Financial reports
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
13 Mar 24
8-K
80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024
14 Dec 23
8-K/A
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
8 Nov 23
8-K
Results of Operations and Financial Condition
8 Nov 23
8-K
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
2 Oct 23
8-K
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
10 May 23
8-K/A
Departure of Directors or Certain Officers
28 Mar 23
8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
28 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
12 Feb 24
S-3
Shelf registration
12 Feb 24
S-8
Registration of securities for employees
29 Mar 23
424B3
Prospectus supplement
4 Nov 22
S-3
Shelf registration
26 Oct 22
D
$72.50 mm in equity / options, sold $72.50 mm, 13 investors
11 Oct 22
424B5
Prospectus supplement for primary offering
18 Mar 22
424B5
Prospectus supplement for primary offering
17 Mar 22
S-8
Registration of securities for employees
17 Mar 22
424B3
Prospectus supplement
4 Oct 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DEFM14A
Proxy related to merger
8 Jul 21
PREM14A
Preliminary proxy related to merger
21 Jun 21
DEFA14A
Additional proxy soliciting materials
9 Jun 21
DEF 14A
Definitive proxy
9 Jun 21
DEFA14A
Additional proxy soliciting materials
4 Jun 21
DEFA14A
Additional proxy soliciting materials
20 May 21
Other
EFFECT
Notice of effectiveness
7 Nov 22
CORRESP
Correspondence with SEC
2 Nov 22
UPLOAD
Letter from SEC
1 Nov 22
EFFECT
Notice of effectiveness
4 Oct 21
CORRESP
Correspondence with SEC
30 Sep 21
UPLOAD
Letter from SEC
29 Sep 21
EFFECT
Notice of effectiveness
16 Apr 21
CORRESP
Correspondence with SEC
13 Apr 21
UPLOAD
Letter from SEC
12 Apr 21
EFFECT
Notice of effectiveness
12 Feb 19
Ownership